Florence Tenenbaum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Florence Tenenbaum has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Bertrand Dousset
Department of Gastrointestinal, Hepatobiliary and Endocrine Surgery, Cochin Hospital, AP-HP (Paris Public Hospitals), 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
4 shared publications - Lionel Groussin
Team « Genomic and Signaling of Endocrine Tumors », Institut Cochin, INSERM U1016- CNRS UMR8104-Université Paris-Cité , 75014 Paris
4 shared publications Bruno Richard
2 shared publications- Cécile Ghander
Service des pathologies thyroïdiennes et tumorales endocrines, hôpital de la Pitié-Salpêtrière, AP-HP, 47-83, Boulevard de l'Hôpital, 75651 Paris cedex, France
2 shared publications - Jérôme Bertherat
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
2 shared publications Paul Legmann
2 shared publications
Latest Publications
- 1 October 2014
- Published by Elsevier in Journal de Chirurgie Viscérale
- Vol. 151 (4) , A18
Résultat de la surrénalectomie laparoscopique pour adénomes cortisoliques infra-cliniques
- 1 October 2014
- Published by Elsevier in Journal de Chirurgie Viscérale
- Vol. 151 (4) , A18
Résultat de la surrénalectomie laparoscopique pour adénomes cortisoliques infra-cliniques
- 1 April 2014
- Published by Elsevier in La Presse Médicale
- Vol. 43 (4) , 410-419
Nouveautés en imagerie surrénalienne
- 1 April 2014
- Published by Elsevier in La Presse Médicale
- Vol. 43 (4) , 410-419
Nouveautés en imagerie surrénalienne
- 1 July 2013
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 74 (3) , 185-190
Topographic diagnosis: Respective roles of morphological and functional imaging
- 1 July 2013
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 74 (3) , 185-190
Topographic diagnosis: Respective roles of morphological and functional imaging
- 1 November 2012
- Published by Elsevier in The Lancet
- Vol. 380 (9854) , 1683
When adrenal Cushing's and phaeochromocytoma meet
- 1 November 2012
- Published by Elsevier in The Lancet
- Vol. 380 (9854) , 1683
When adrenal Cushing's and phaeochromocytoma meet
- 1 April 2012
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (4) , 1096-1097
A Concomitant False-Negative 18 F-FDG PET Imaging in an Adrenocortical Carcinoma and a High Uptake in a Corresponding Liver Metastasis
- 1 April 2012
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (4) , 1096-1097
A Concomitant False-Negative 18 F-FDG PET Imaging in an Adrenocortical Carcinoma and a High Uptake in a Corresponding Liver Metastasis
- 1 June 2004
- Published by Bioscientifica in European Journal of Endocrinology
- Vol. 150 (6) , 789-792
18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients
DESIGN: This study is a preliminary report on 18F-fluorodeoxyglucose (18F-FDG) uptake for the characterization of hypersecretory or non-hypersecretory adrenocortical masses in patients without known neoplastic disease, thereby minimizing the presence of adrenal metastases, and without phaeochromocytoma, in comparison with computed tomography (CT) scanning and with iodocholesterol scintigraphy. METHODS: Thirteen consecutive patients with an adrenal mass scheduled to have surgery, underwent hormonal exploration, a CT scan for tumour size measurement and an 18F-FDG positron emission tomography scan. Eleven of these patients also had unenhanced density measurement at CT scan and iodocholesterol scintigraphy. RESULTS: CT-scanned adrenal masses ranged in size from 2.2 to 10 cm; attenuation value was 10 HU in nine. All benign lesions demonstrated iodocholesterol uptake. In the case of malignant tumours, results were non-homogeneous: no uptake, uptake and non-informative scintigraphy. All patients with an adrenocortical carcinoma had positive adrenal 18F-FDG uptake (n=3), one had a liver metastasis with positive 18F-FDG uptake, one showed 18F-FDG uptake in an adrenal metastasis from an unknown primary kidney tumour. All patients with a benign adrenocortical lesion had negative 18F-FDG uptake (n=9). Patients' lesions were hypersecretory (n=5), or non-hypersecretory (n=8), regardless of the pathology. CONCLUSION: This short preliminary study indicates that 18F-FDG gave a correct classification of tissue characterization with accurate identification of malignant lesions, as well as the disease stage (metastasis or primary). These promising preliminary results on adrenocortical lesions, seldom studied with 18F-FDG, are to be confirmed in larger series.
- 1 June 2004
- Published by Bioscientifica in European Journal of Endocrinology
- Vol. 150 (6) , 789-792
18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients
DESIGN: This study is a preliminary report on 18F-fluorodeoxyglucose (18F-FDG) uptake for the characterization of hypersecretory or non-hypersecretory adrenocortical masses in patients without known neoplastic disease, thereby minimizing the presence of adrenal metastases, and without phaeochromocytoma, in comparison with computed tomography (CT) scanning and with iodocholesterol scintigraphy. METHODS: Thirteen consecutive patients with an adrenal mass scheduled to have surgery, underwent hormonal exploration, a CT scan for tumour size measurement and an 18F-FDG positron emission tomography scan. Eleven of these patients also had unenhanced density measurement at CT scan and iodocholesterol scintigraphy. RESULTS: CT-scanned adrenal masses ranged in size from 2.2 to 10 cm; attenuation value was 10 HU in nine. All benign lesions demonstrated iodocholesterol uptake. In the case of malignant tumours, results were non-homogeneous: no uptake, uptake and non-informative scintigraphy. All patients with an adrenocortical carcinoma had positive adrenal 18F-FDG uptake (n=3), one had a liver metastasis with positive 18F-FDG uptake, one showed 18F-FDG uptake in an adrenal metastasis from an unknown primary kidney tumour. All patients with a benign adrenocortical lesion had negative 18F-FDG uptake (n=9). Patients' lesions were hypersecretory (n=5), or non-hypersecretory (n=8), regardless of the pathology. CONCLUSION: This short preliminary study indicates that 18F-FDG gave a correct classification of tissue characterization with accurate identification of malignant lesions, as well as the disease stage (metastasis or primary). These promising preliminary results on adrenocortical lesions, seldom studied with 18F-FDG, are to be confirmed in larger series.
- 1 February 2003
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 28 (2) , 157-159
Ga-67 in Castleman’s Disease
- 1 February 2003
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 28 (2) , 157-159
Ga-67 in Castleman’s Disease